Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ION-682884 in TTR Amyloidosis Cardiomyopathy
NCT04843020Phase 2Withdrawn
- Sponsor
- Brigham and Women's Hospital
- Start
- Jun 2021
- Primary completion
- May 2025
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eplontersen in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by Brigham and Women's Hospital. Primary endpoints: Echocardiographic change at 48 months, Change in cardiac MRI at 48 months and 4 more. Planned start Jun 2021; status: withdrawn.
02
Drugs
eplontersen
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT04843020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04843020.